GlassScriptPhysician profile
Maria Dutra
NPI 1194790428
$1,214.46
in general payments reported to CMS, 2019-2025
13 companies · $22.25 in 2025
The $22.25 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $310 · 2022: $420 · 2023: $428 · 2024: $34.03 · 2025: $22.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.21 | 2021-2025 | |
| Janssen Biotech, INC. | $320.98 | 2022-2023 | Stelara, Simponi Aria, Remicade |
| Nestle Healthcare Nutrition INC. | $70.49 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $63.22 | 2022-2023 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $61.69 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $48.16 | 2022-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.84 | 2021-2022 | |
| Ardelyx, INC. | $38.54 | 2023 | Ibsrela |
| Gilead Sciences, INC. | $35.32 | 2022-2023 | |
| Daiichi Sankyo INC. | $16.48 | 2021 | |
| Fresenius Kabi USA, LLC | $16.45 | 2023 | |
| Redhill Biopharma INC. | $15.95 | 2021 | |
| Lilly USA, LLC | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Dutra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.